Agile Sciences receives NIH STTR grant to evaluate anti-biofilm compounds for treating cystic fibrosis in collaboration with Dr. Richard Boucher at UNC Chapel Hill. News release.
Agile Sciences and Calvert Research announce strategic collaboration. News release.
A $545,000 NIH Phase I SBIR SHIFT Grant is awarded to Agile Sciences to support human therapeutic development. News release.
Agile Sciences is awarded a NIH Phase I STTR Grant to evaluate technology in chronic wound models at the Center for Biofilm Engineering at Montana State Universtiy. News release.
Agile Sciences' collaboration with scientists at NC State University results in the identification of Agilyte-modified polymers that resist bacterial colonization. This work was funded by a NSF STTR Grant and has been published in Chemical Communications.
Filtration membrane expert Dr. Thomas Engelhardt joins Agile Sciences' Scientific Advisory Board. News release.
Second US Patent is issued, expanding Agile Science's proprietary compound library. News release.
Agile Sciences receives a grant from the Cystic Fibrosis Foundation. News release.
Agile Sciences announces issuance of U.S. Patent for biofilm dispersing compounds. News release.
Agile is granted a $150,000 NSF Phase I Award to incorporate its proprietary anti-biofilm small molecules into medical devices. News release.
Agile Sciences moves into a new, larger facility on NC State's Centennial Campus. News release.
Agile co-founders are awarded a $1.8 million grant from the Department of Defense to develop molecules for treating multi-drug resistant infections. News release.
Agile receives a $252,000 NIH SBIR award to validate Agile's biofilm dispersion technology for dental applications. News release.
Agile has been awarded a $570,000 2-year NIH SBIR Grant for applying Agile's anti-biofilm technology to hydrocephalus shunts. News release.
Agile announces research and development agreement with a multinational chemical company to screen Agile's compounds for effectiveness in agriculture. News release.
SePRO Corporation strengthens its partnership with Agile Sciences through Board participation and equity investment News release.
Synergistic effects between conventional antibiotics and Agile's antibiofilm agents are reported in Antimicrobial Agents and Chemotherapy. View news release.
Agile's Technology is Presented at the Center for Biofilm Engineering Technical Advisory Conference View poster.
Agile Sciences and SePRO Corporation announce an agreement to develop Agile Sciences' technology for use in Turf and Ornamental applications. News release.
Agile Sciences enters technology development and commercialization agreement with SePRO Corporation to apply Agile Sciences' proprietary compound to Aquatics applications. News release.
Agile Sciences' co-founders discuss Agile's Technology on Radio in Vivo. Link to podcast.
Agile Sciences is awarded a $150,000 NSF STTR Grant to apply Agile's anti-biofilm technology toward membrane filtration. News release.
A new class of compounds that both inhibit and disperse MRSA, vancomycin-resistant Enterococcus faecium, and Staphylococcus epidermidis biofilms has been reported in the Journal of the American Chemical Society by Agile Sciences' co-founder, Dr. Christian Melander.
The North Carolina Biotechnology center issues a news release announcing that a $50,000 Company Inception Loan has been awarded to Agile Sciences.
Agile Sciences' technology is spotlighted in a front page article in The News and Observer: "Slime-fighting molecules may rearm antibiotics"
Agile Sciences' co-founders discuss Agile's anti-biofilm compounds in a Washington Post article: "Scientists Learning to Target Bacteria Where They Live"
Agile Sciences' technology is featured on the Science Magazine website, in an article entitled "Sponging Away Antibiotic Resistance"
Agile Sciences' co-founders Dr. Christian Melander and Dr. John Cavanagh have discovered that Agile Sciences' proprietary compound, Agilyte™, is able to re-sensitize multi-drug resistant bacteria to the effects of conventional antibiotics. The bacterial strains tested include MRSA and multi-drug resistant Acinetobacter baumannii. These results may have significant impact on the treatment of infectious disease, specifically potential re-use of conventional antibiotics that have been rendered obsolete due to the development of resistance by the bacterial population.
Agile Sciences' founders have won a University of North Carolina General Administration Competitiveness Grant in the amount of $200,000 for continuing work on anti-biofilm agents that also modulate broad bacterial response. This is the second UNC-GA award given to Drs. Cavanagh and Melander for these studies, showing that there is significant perceived promise in the technology and that all of the research milestones to date have been achieved.
Agile co-founders Christian Melander and John Cavanagh are awarded a $312,000 grant from the North Carolina Biotechnology Center to study the effect of an Agile compound on Bacterial Spot Disease. These studies will be conducted on pepper plants grown both in greenhouses and in fields.
The first example of a nonbactericidal small molecule that inhibits and disperses biofilms across bacterial order, class and phylum is published in Angewandte Chemie by Agile Sciences' co-founder Dr. Christian Melander.
Agile Sciences co-founder, Dr. John Cavanagh, is chosen to lead V Foundation-NCSU Cancer Therapeutic Training program – see press release. Read more...
An Agile compound has been found to be 100% effective in inhibiting Xanthomonas biofilm formation in a strain that causes bacterial spot disease on peppers.
Agile founders show that simple derivatives of their core pharmacophore are capable of inhibiting and dispersing biofilms. These results are highlighted in Chemical Biology.
Agile founders discover molecules that inhibit and disperse bacterial biofilms across bacterial order and publish their findings in Chemical Communications.
Agile's founders have won a University of North Carolina General Administration Competitiveness Grant in the amount of $300,000 to further their research on biofilm inhibition.
The founders of Agile are featured in Results, the magazine of Research and Graduate Studies at NC State.
Agile founders' work on inhibiting Vibrio infections is featured in Scope Magazine. View the article (PDF, 174KB).
Professor Cavanagh's work on biofilms is spotlighted by The Magazine of the College of Agriculture and Life Sciences at NC State.